NCT04289259View on ClinicalTrials.gov

Tumor Mutational Burden in Lung Cancer Patients

TerminatedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

July 6, 2020

Study Completion Date

July 6, 2020

Conditions
Non Small Cell Lung CancerNon-Small Cell Carcinoma of LungNon Small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IV
Interventions
OTHER

TMB assessment

Tumor mutational burden could be calculated by cancer gene panel (CGP), whole-exome sequencing (WES), RNA-sequencing (RNA-seq), FoundationOne CDx assay panel (FMI).

Trial Locations (8)

33000

Institut Bergonié, Bordeaux

63000

Centre Jean Perrin, Clermont-Ferrand

69008

Centre Léon Bérard, Lyon

75005

Institut Curie, Paris

75014

AP-HP - Hôpital Cochin, Paris

75015

AP-HP - Hôpital Européen Georges-Pompidou, Paris

75020

AP-HP - Hôpital Tenon, Paris

94800

Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04289259 - Tumor Mutational Burden in Lung Cancer Patients | Biotech Hunter | Biotech Hunter